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The research field on e-cigarettes is characterized by severe methodological problems, severe conflicts of interest, relatively
few and often small studies, inconsistencies and contradictions in results, and a lack of long-term follow-up. Therefore, no
firm conclusions can be drawn on the harm of e-cigarettes, but they can hardly be called safe. Experimental studies indicate
negative health effects and, amongst others, the major ingredient propylene glycol warrants concern. Growing evidence
raises doubt about the efficacy of e-cigarettes as a smoking cessation aid. Unfortunately, it seems that many smokers
use e-cigarettes with the intention to quit but switch to long-term use of e-cigarettes or dual use. Use is spreading
rapidly to minors, ex-smokers, and never-smokers. It is questionable whether the potential health benefits obtained by
some smokers outweigh the potential harm by use of non-smokers, of undermining of complete cessation, smokers’
dual use, and of eventual re-normalization of smoking. Even if e-cigarettes are significantly less harmful than
conventional cigarettes, the product may have a very negative impact on public health if its use is spread to a
large part of the population.
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When I first heard about the e-cigarette (EC), I was ex-
cited. Was this the miraculous alternative to conventional
cigarettes (CC) that could prevent millions of peoples’ suf-
fering? Today, big tobacco companies have bought up the
market, sales are exploding, and I and many other health
professionals are worried [1].
Some harm reduction advocates claim that public health
professionals are just moralists with an aversion of nico-
tine, an addictive drug, leading to an illogical and unfair
hatred of ECs. I believe this subject is of too large public
health importance to resort to mudslinging.
The harm reduction strategy (replacing a very harmful
product with a less harmful product) is common sense;
however, history has unfortunately shown that common
sense can do harm [2]. As a doctor, I have sworn “First
Do No Harm”, as a researcher, I call for substantial evi-
dence with very consistent findings, and as a public health
professional, I am obliged to take long-term consequences
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unless otherwise stated.smokers – into account before recommending a new
product.The safety of e-cigarettes
ECs are marketed as safe products delivering pure nico-
tine and releasing harmless water vapor that vanishes in
seconds [3,4], but is this true? The research field is char-
acterized by severe methodological problems, severe
conflicts of interest, relatively few and often small stud-
ies, inconsistencies and contradictions in results, and a
lack of long-term follow-up. Therefore, no firm conclu-
sions can be drawn on the safety of ECs [5,6], and much
is left to subjective interpretations. Most probably ECs
are less harmful than conventional cigarettes, but they
can hardly be called safe. An experimental study found
that cells exposed to high-nicotine vapor showed a similar
pattern of gene expression to those exposed to tobacco
smoke [7]. Very short-term experimental exposure to EC
vapor showed effects that are reminiscent of the obstruct-
ive effects seen with smoking [8-10], even though the
impact on lung function was smaller than with smok-
ing. An experimental animal study found that EC fluid
can exacerbate allergy-induced asthma symptoms [11].
Furthermore, a study found that the vapor inducedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[12] and many studies have found cytotoxicity [13,14]
and harmful substances in fluid and vapor (e.g., fine or
ultrafine particles [15-17], harmful metals [13,18], car-
cinogenic tobacco-specific nitrosamines [19-23], carbonyls
[19,21,24,25], volatile organic compounds [19,26], poly-
cyclic aromatic hydrocarbons [18,22]) or in urine [18].
It is true that most studies found low or very low con-
centrations, but values below the threshold-limit do not
necessarily protect against a negative health effect of
200 to 300 daily inhalations [27] over decades.
The EC is a radically different product than the CC
and, therefore, it seems wrong to base an assessment of
the safety of EC on comparisons with CCs only. Of
special concern are compounds not found in CCs: the
glycols (propylene glycol and sometimes glycerin) are
major ingredients of ECs [28-32] used to create the
visible fume. A report commissioned by vapers and
vendors of ECs concluded that “estimated levels of exposure
to propylene glycol and glycerin are close enough to
threshold-limit values to warrant concern” and that “the
threshold-limit value is based on uncertainty rather than
knowledge” [33]. Several studies on glycols have raised
health concerns [34-37]. Other concerns are the flavors,
metals, and silicone [13,14,38]. Finally, nicotine itself is




















Figure 1 The long-term impact of smoking and e-cigarette use on pub
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that smokers wish to quit and tobacco control efforts are effective. Smoking r
Smoking scenario 3 (worst case): EC-use might undermine smoking cessation a
increase. The harm indicated as squared is the extra harm indirectly caused b
the theory we might underestimate long-term harm of ECs, and use of EC
the population use ECs, harm = 10. EC-scenario 4: 30% of the population u
use ECs, harm = 25.Studies show that non-smokers passively exposed to ECs
absorb nicotine [18,40,41].Use of e-cigarettes is no longer restricted to smokers
In the first years, the ECs were bought by smokers only;
however, recently, their use has also spread to ex-smokers
[42-45] and never smokers [45-49]. The intensive market-
ing, the novelty, the use of celebrities as role models, and
the candy-like flavors appeal to young people. Experimen-
tal use in minors has doubled within one year [45,48,50]. A
high proportion of adolescents have tried ECs [46,47,49],
even at age 12 to 14 years [47]. Of special concern is that
young never-smokers are experimenting with ECs [45-49]
and the use of ECs might undermine decades of efforts to
de-normalize smoking [51]. A brand new study from
Poland finds that almost every third adolescent is current
user of ECs and more than every fifth has a dual use of
CCs and ECs. However, the most alarming finding is that
the prevalence of smoking increased with increasing rates
of EC use, from 24% to 38% during a period of only three
years, indicating a renormalization of smoking [52].
It would be naïve not to expect that the manufacturers
will try hard to spread the use of their product to as
many consumers as possible, and history has shown that









lic health – year 2050. The risk models are based on assumptions of
ttes (EC). Harm of smoking is known to be extremely high; this is our
f EC-use is estimated as extremely low/very low = 1 or 5. In a public
or 25. Harm reduction perspective: Smoking scenario 1: the theory
h (15% smokers, harm =100). E-cigarette scenarios: the theory assumes
okers only. EC-scenario 1: 10% of the population use ECs, harm = 1.
harm = 5. Public health perspective: Smoking scenario 2: the theory is
ates will reduce steadily over the next decades (5% smokers, harm =100).
nd renormalize conventional smoking, and the smoking rates might
y ECs (30% smokers, harm = 100). E-cigarette scenarios: according to
s might spread to a large part of the population EC-scenario 3: 20% of
se ECs, harm = 15. EC-scenario 5 (worst case): 40% of the population
Health gain for reluctant 
smokers  who switch to EC
Increased risk for never 
smokers using EC
Increased risk for smokers
who switch to EC instead
of stopping smoking 
Re-normalisation of 
smoking in society
Increased risk for smokers
by dual use (smoking + EC)  
Health gain for smokers 
who quit y use of EC
Increased risk for ex-
smokers using EC
Health gain for smokers 
who substantially reduce
smoking by use of EC
Figure 2 The difficult balance between the potential pros and cons of e-cigarettes. The public health perspective.
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cessation
Making strong conclusions based on smoking rates
and rates of EC-use in different countries is difficult, as
smoking rates are influenced by political decisions as price
and availability, changes in the social norm, etc. Some pro-
spective studies were very promising [54,55], and a recent
large ‘real-world’ study taking smoker’s addiction into
account showed that use of ECs increased cessation rates
more than no aid/nicotine replacement products bought
over the counter [56]. However, a meta-analysis based
on five population-based studies found that EC users
were significantly less likely than non-users to have
stopped smoking [6], a longitudinal study in cancer
patients showed that EC users were twice as likely to
be smoking at the time of follow-up as non-users [57],
and the only existing randomized smoking cessation
study showed that ECs were not significantly more
effective than nicotine patch therapy [58]. A survey spon-
sored by EC manufacturers found that only 1% of EC
users achieved permanent abstinence [59], but I have not
seen this study cited by harm reduction advocates. Unfor-
tunately, it seems that many smokers use ECs with the
intention to quit but switch to long-term use of ECs [58]
or end with dual use, supplementing their smoking with
the EC [42-44,60] – dream-scenarios for the industry.
Impact on public health
When we compare with a CC, the most harmful legal
product on the market, everything seems harmless. For a
smoker reluctant to stop smoking, the EC will most
probably be a less harmful alternative – but we cannot
focus on these smokers only! The impact of a product
on public health is determined by two factors: i) thedegree of toxicity or harm of the substance; and ii) how
widespread the exposure is. Even if ECs are significantly
less harmful than CCs, the product may have a negative
impact on public health if the use is spread to a large
part of the population (Figure 1). ECs might achieve
popularity as high as that of CCs in the 1960s, before an
awareness of harm became widespread in the popula-
tion. The potential health benefits obtained by some
smokers (Figure 2) must outweigh the potential harm by
use of ex- and never-smokers, of smokers who intended
to quit but switched to ECs, of smokers’ dual use, and of
eventual re-normalization of smoking.Conclusions
Most probably, ECs are less harmful than CCs, but they
can hardly be called safe. Consequences of EC use must
be viewed in a long-term public health perspective, includ-
ing both smokers and non-smokers. Based on the limited
and often conflicting evidence on safety, the doubtful effi-
cacy as a smoking cessation aid, and the alarming rise in
use in young people and non-smokers, most public health
professionals urge great caution with ECs and call for
regulation, monitoring, and research not biased by con-
flicts of interest.
As the WHO states, this is an “evolving frontier filled
with promise and threat for tobacco control” [1]. I shall
be the first to celebrate if the ECs turn out to be a safe
and effective weapon in tobacco control. Till then, let us
focus on intensifying our fight for a smoke-free world by
restricting the influence of the tobacco industry, by
regulating smoking and other tobacco-/nicotine contain-
ing products, and by offering evidence-based help for
smoking cessation – we know this works.
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